Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct.

Helus Pharma to Host Investor Presentation on October 21, 2026

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name